Geode Capital Management LLC Raises Stake in ProKidney Corp. (NASDAQ:PROK)

Geode Capital Management LLC raised its stake in shares of ProKidney Corp. (NASDAQ:PROK - Free Report) by 102.0% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,203,934 shares of the company's stock after buying an additional 1,112,933 shares during the quarter. Geode Capital Management LLC owned about 0.76% of ProKidney worth $4,232,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds have also recently modified their holdings of PROK. Suvretta Capital Management LLC boosted its stake in ProKidney by 32.1% during the third quarter. Suvretta Capital Management LLC now owns 12,341,266 shares of the company's stock valued at $23,695,000 after buying an additional 3,000,000 shares during the last quarter. Charles Schwab Investment Management Inc. raised its holdings in shares of ProKidney by 150.6% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 749,718 shares of the company's stock worth $1,439,000 after acquiring an additional 450,548 shares in the last quarter. State Street Corp boosted its position in shares of ProKidney by 16.2% during the 3rd quarter. State Street Corp now owns 1,428,318 shares of the company's stock valued at $2,742,000 after acquiring an additional 198,836 shares during the last quarter. Barclays PLC grew its holdings in shares of ProKidney by 575.7% in the third quarter. Barclays PLC now owns 146,321 shares of the company's stock valued at $281,000 after purchasing an additional 124,667 shares in the last quarter. Finally, Bank of New York Mellon Corp increased its position in ProKidney by 44.6% in the second quarter. Bank of New York Mellon Corp now owns 179,236 shares of the company's stock worth $441,000 after purchasing an additional 55,266 shares during the last quarter. Institutional investors own 51.59% of the company's stock.

ProKidney Stock Performance

PROK stock traded down $0.05 during mid-day trading on Monday, reaching $1.81. 676,049 shares of the stock traded hands, compared to its average volume of 782,583. ProKidney Corp. has a one year low of $1.18 and a one year high of $4.44. The stock has a market capitalization of $527.91 million, a PE ratio of -3.29 and a beta of 1.32. The business has a 50-day moving average price of $1.82 and a two-hundred day moving average price of $2.04.

ProKidney (NASDAQ:PROK - Get Free Report) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($0.14) EPS for the quarter, meeting the consensus estimate of ($0.14). On average, equities analysts expect that ProKidney Corp. will post -0.57 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several equities analysts have commented on PROK shares. Guggenheim started coverage on shares of ProKidney in a research report on Tuesday, September 10th. They set a "buy" rating and a $6.00 price objective for the company. JPMorgan Chase & Co. initiated coverage on shares of ProKidney in a report on Monday, September 30th. They issued a "neutral" rating for the company. Three investment analysts have rated the stock with a hold rating and two have given a buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of "Hold" and a consensus price target of $4.50.

About ProKidney

ProKidney Corp., a clinical-stage biotechnology company, provides transformative proprietary cell therapy platform for treating various chronic kidney diseases in the United States. The company's lead product is Renal Autologous Cell Therapy (REACT), an autologous homologous cell admixture, which has completed Phase I clinical trial for REACT in patients with congenital anomalies of the Kidney and Urinary Tract (CAKUT), as well as in Phase III and Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease.